Related Experiment Video
Updated: Nov 2, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
Alejandro Garcia-Alvarez1, Carolina Ortiz1, Eva Muñoz-Couselo1
1Vall d'Hebron University Hospital, Medical Oncology Department, Melanoma and Other Skin Tumors Unit, Vall Hebron Institute of Oncology (VHIO), Barcelona, 08035, Spain.
Abstract:
Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in 20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer outcomes, compared to non-NRAS-mutant melanoma. Despite promising preclinical data, to date immune checkpoint inhibitors remain the standard of care for locally advanced unresectable or metastatic NRAS melanoma. Data for efficacy of immunotherapy for NRAS melanoma mainly come from retrospective cohorts with divergent conclusions. MEK inhibitors have been the most developed targeted therapy approach. Although associated with an increase in progression-free survival, MEK inhibitors do not provide any benefit in terms of overall survival. Combination strategies with PI3K-AKT-mTOR pathway and CDK4/6 inhibitors seem to increase MEK inhibitors' benefit. Nevertheless, results from clinical trials are still prelaminar. A greater comprehension of the biology and intracellular interactions of NRAS-mutant melanoma will outline novel impactful strategies which could improve prognosis of these subgroup of patients.
Insights
NRAS-mutant melanoma is an aggressive skin cancer with poor outcomes. Current treatments like immune checkpoint inhibitors and MEK inhibitors show limited survival benefits, necessitating further research into novel therapeutic strategies.
Area of Science:
- Oncology
- Dermatology
- Cancer Biology
Background:
- Melanoma is the deadliest skin cancer, with activating NRAS mutations occurring in 20% of cases.
- NRAS-mutant melanoma exhibits increased aggressiveness and poorer patient prognoses compared to non-NRAS-mutant melanoma.
- Current standard of care for advanced NRAS-mutant melanoma involves immune checkpoint inhibitors, despite limited efficacy data from retrospective studies.
Purpose of the Study:
- To review the current therapeutic landscape for NRAS-mutant melanoma.
- To highlight the limitations of existing treatments, including immune checkpoint inhibitors and MEK inhibitors.
- To emphasize the need for a deeper understanding of NRAS-mutant melanoma biology to develop novel treatment strategies.
Main Methods:
- Review of existing literature on NRAS-mutant melanoma treatment efficacy.
- Analysis of data regarding immune checkpoint inhibitors and targeted therapies (MEK inhibitors).
- Exploration of potential combination strategies involving PI3K-AKT-mTOR and CDK4/6 inhibitors.
Main Results:
- Immune checkpoint inhibitors are the standard of care, but efficacy data for NRAS-mutant melanoma are conflicting.
- MEK inhibitors improve progression-free survival but not overall survival in NRAS-mutant melanoma.
- Combination therapies (e.g., with PI3K-AKT-mTOR or CDK4/6 inhibitors) show potential but require further clinical validation.
Conclusions:
- Novel therapeutic strategies are urgently needed to improve outcomes for patients with NRAS-mutant melanoma.
- A comprehensive understanding of NRAS-mutant melanoma's intracellular biology is crucial for developing impactful treatments.
- Further clinical trials are essential to evaluate the efficacy of emerging combination therapies.
Related Concept Videos
02:23Abnormal Proliferation
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...